DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital)

N/A

Report date: 2025/09/16 20:00:07

Base Information

Drug NameDLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital)
Drug Alias NameDLL3-CAR-NK cellsDLL3-CAR-NK cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionDelta-like protein 3 modulators
TargetsDelta-like protein 3
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTianjin Medical University Cancer Institute And Hospital
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Medical University Cancer Institute And Hospital
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A